Q3 2017 13F Holders as of 9/30/2017
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
61.4M
-
Number of holders
-
41
-
Total 13F shares, excl. options
-
8.13M
-
Shares change
-
+5.83K
-
Total reported value, excl. options
-
$144M
-
Value change
-
+$619K
-
Number of buys
-
21
-
Number of sells
-
-15
-
Price
-
$17.67
Significant Holders of Protagonist Therapeutics, Inc - Common Stock (PTGX) as of Q3 2017
47 filings reported holding PTGX - Protagonist Therapeutics, Inc - Common Stock as of Q3 2017.
Protagonist Therapeutics, Inc - Common Stock (PTGX) has 41 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 8.13M shares
of 61.4M outstanding shares and own 13.24% of the company stock.
Largest 10 shareholders include FMR LLC (2.54M shares), ADAGE CAPITAL PARTNERS GP, L.L.C. (2.06M shares), Pharmstandard International S.A. (982K shares), Cormorant Asset Management, LLC (500K shares), BlackRock Inc. (448K shares), VANGUARD GROUP INC (356K shares), SENZAR ASSET MANAGEMENT, LLC (221K shares), Polar Capital LLP (150K shares), MILLENNIUM MANAGEMENT LLC (137K shares), and EVENTIDE ASSET MANAGEMENT, LLC (125K shares).
This table shows the top 41 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.